Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Antimicrobial treatment of non-cystic fibrosis bronchiectasis

Grimwood, Keith, Bell, Scott C. and Chang, Anne B. (2014). Antimicrobial treatment of non-cystic fibrosis bronchiectasis. Expert Review of Anti-Infective Therapy,12(10):1277-1296.

Document type: Journal Article
Citation counts: Altmetric Score Altmetric Score is 12
Google Scholar Search Google Scholar

IRMA ID 84473293xPUB4
Title Antimicrobial treatment of non-cystic fibrosis bronchiectasis
Author Grimwood, Keith
Bell, Scott C.
Chang, Anne B.
Journal Name Expert Review of Anti-Infective Therapy
Publication Date 2014
Volume Number 12
Issue Number 10
ISSN 1478-7210   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-84907046532
Start Page 1277
End Page 1296
Total Pages 20
Place of Publication United Kingdom
Publisher Taylor & Francis
HERDC Category C1 - Journal Article (DIISR)
Abstract Bronchiectasis unrelated to cystic fibrosis is characterized by chronic wet or productive cough, recurrent exacerbations and irreversible bronchial dilatation. After antibiotics and vaccines became available and living standards in affluent countries improved, its resulting reduced prevalence meant bronchiectasis was considered an ‘orphan disease’. This perception has changed recently with increasing use of CT scans to diagnose bronchiectasis, including in those with severe chronic obstructive pulmonary disease or ‘difficult to control’ asthma, and adds to its already known importance in non-affluent countries and disadvantaged Indigenous communities. Following years of neglect, there is renewed interest in identifying the pathogenetic mechanisms of bronchiectasis, including the role of infection, and conducting clinical trials. This is providing much needed evidence to guide antimicrobial therapy, which has relied previously upon extrapolating treatments used in cystic fibrosis and chronic obstructive pulmonary disease. While many knowledge gaps and management challenges remain, the future is improving for patients with bronchiectasis.
Keywords amikacin
azithromycin
bronchiectasis
colistin
Haemophilus influenzae
microbiota
non-tuberculous mycobacteria
Pseudomonas aeruginosa
respiratory viruses
tobramycin
DOI http://dx.doi.org/10.1586/14787210.2014.952282   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 25 Abstract Views  -  Detailed Statistics
Created: Wed, 19 Aug 2015, 12:31:40 CST